Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5593024 | Clínica e Investigación en Arteriosclerosis | 2017 | 12 Pages |
Abstract
Familial hypercholesterolemia (FH) is the most common genetic disorder in childhood, but in most cases is not detected. High levels of low-density lipoprotein cholesterol are present since the child's birth and this fact will suppose silent development of early atherosclerosis. In cases of homozygous FH, the coronary disease will appear before 20s and in cases of heterozygous FH will occur in middle age. Despite published data, there is not agreement about how and when perform the screening. Familial history of early cardiovascular disease plus presence of hypercholesterolemia in parents is crucial for detection and diagnosis. Actually, it is topic of discussion that it is necessary to achieve therapeutic goals from an early age to improve prognosis. Lifestyle changes are the first line therapy. Statins are the lipid-lowering drugs of choice but the optimal age to start therapy it is still controversial. In this article, current recommendations of expert consensus guidelines about the management and new line therapies of child and adolescents are reviewed.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Physiology
Authors
Núria Plana, Cèlia RodrÃguez-Borjabad, Daiana Ibarretxe, LluÃs Masana,